Mark W. Lingen to Follow-Up Studies
This is a "connection" page, showing publications Mark W. Lingen has written about Follow-Up Studies.
Connection Strength
0.114
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.026
-
Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
Score: 0.024
-
Solitary intraoral keratoacanthoma: report of a case. J Oral Maxillofac Surg. 1996 Aug; 54(8):1026-30.
Score: 0.022
-
Myofibromas of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Sep; 80(3):297-302.
Score: 0.020
-
Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):664-72.
Score: 0.016
-
Acellular dermal matrix allografts to achieve increased attached gingiva. Part 1. A clinical study. J Periodontol. 2000 Aug; 71(8):1297-305.
Score: 0.007